These changes could show up as light spotting between periods, cycles, longer cycles, unpredictable bleeding patterns, extended periods of no bleeding at all, heavier flow during periods, and experiencing menstrual cramps from time to time
The most frequent adverse events were mainly mild-to-moderate gastrointestinal events, which reduced over time."The magnitude of weight loss observed with retatrutide has the potential to slow disease progression and reshape how we treat and manage type 2 diabetes," Bajaj said in a statement.Several authors disclosed ties to biopharmaceutical companies, including Eli Lilly, which is developing retatrutide and funded the study.Abstract/Full Text (subscription or payment may be required)More Information.Sign up for our weekly HealthDay newsletter
It should also be noted that, from a methodological perspective, the model used (Cox with stratification by cardiovascular risk class of the trials, i.e., SURPASS-4: high risk, and all others: low risk) requires various assumptions, including the homogeneity of the relative effect of tirzepatide treatment on MACE regardless of the baseline cardiovascular risk level of the patients
About King Law King Law is a reputable personal injury and mass tort firm
MEDVi Personalized GLP-1 Medication is a treatment designed to help manage blood sugar levels and assist in weight loss for individuals with type 2 diabetes or obesity
The Science of Semaglutide: A GLP-1 Overview Semaglutide is the active ingredient found in several well-known medications, including Ozempic, Wegovy, and Rybelsus